Gastroenterology Unit, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Curr Med Chem. 2010;17(17):1851-7. doi: 10.2174/092986710791111170.
Inflammatory bowel diseases are chronic diseases that affect the gastrointestinal tract. Mesalamine, corticosteroids, immunosuppressants and biological agents are currently used to treat these diseases. Due to inadequacies of the currently available delivery systems, a large number of patients do not respond to treatment, especially when they are affected by distal colonic disease. Multimatrix (MMX) technology comprises hydrophilic and lipophilic excipients, enclosed within a gastro-resistant, pH-dependent coating. This new delivery technology has been used to modify some commonly used drugs, including mesalamine and budesonide, as well as heparin, which are now being investigated for their utility in the management of IBD.
The aim of this review is to explore the MMX delivery technology and its efficacy for the treatment of IBD.
The results of various studies involving MMX drugs have been published. Mesalamine MMX induces clinical and endoscopic remission in patients with mild to moderate ulcerative colitis (UC) compared with placebo. Positive results have also been observed with MMX budesonide in two phase I studies. In a pilot study involving ten patients with UC, efficacy of heparin-MMX as an IBD therapy was observed.
MMX is a promising new delivery system that can improve efficacy of current and new drugs, augmenting targeting to the affected tract, thereby increasing response and remission rates for those drugs in patients with IBD.
本综述旨在探讨 MMX 递药技术及其在治疗 IBD 方面的疗效。
已发表了涉及 MMX 药物的多项研究结果。与安慰剂相比，美沙拉嗪 MMX 可诱导轻中度溃疡性结肠炎（UC）患者的临床和内镜缓解。在两项 MMX 布地奈德的 I 期研究中也观察到了阳性结果。在一项涉及 10 例 UC 患者的初步研究中，观察到肝素-MMx 作为 IBD 治疗药物的疗效。
MMX 是一种很有前途的新型递药系统，可提高现有和新型药物的疗效，增强对病变部位的靶向作用，从而提高 IBD 患者对这些药物的应答率和缓解率。
